Rated 4.9 out of 5 based on 11 customer ratings (11 customer reviews) 560.00 AED Blend composition 4 actives 80mg total peptide content GHK-Cu 50mg 62.5% BPC-157 10mg 12.5% TB-500 10mg 12.5% KPV 10mg 12.5% Purity 99.47% Form Lyophilized powder Certificate of Analysis 99.47% Tested purity 99.47% Measured content 95.53mg Test date 14/06/2026 Current batch NVKL80-01052026 Issued by an accredited independent laboratory and tied to this peptide
related full-length recombinant thymosin beta-4 (a different formulation than the marketed TB-500 fragment) has also been examined in small human studies for cardiac and dermatologic indications Examined in preclinical models, including diabetic rat Achilles tendon and rat ligament-injury studies, for actin-binding, cell-migration, and angiogenic activity that researchers have proposed as a mechanism for tendon and ligament repair, though this literature remains comparatively sparse for musculoskeletal applications specifically Known risks and side effects: Because TB-500 is manufactured and sold without FDA oversight as a "research chemical," independent testing and industry reporting describe wide variability in purity (with some products measured well below labeled potency) and contamination with heavy metals or bacterial byproducts, unlike pharmaceutical-grade recombinant thymosin beta-4 used in registered clinical trials Thymosin beta-4's core mechanisms, angiogenesis and cell migration, are also pathways exploited by tumors
Bulletin de la Socit d'Encouragement pour l'Industrie Nationale (in French)
(2011), since transactivation during glutamate oxidation can provide the needed aspartate (Figure 3B), but GDH-mediated -ketoglutarate cannot
Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinsons disease
